Induction of cytokines and growth factors by rapamycin in the microenvironment of brain metastases of lung cancer

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 953-958

  Kim, Se Hoon ^a   Lee, Jung Eun ^b   Yang, Seung Ho ^b   Lee, Sang Won ^b  

^a Yonsei University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Astrocytes; Brain metastasis; Microenvironment; Non small cell lung cancer; Rapamycin

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN METASTASIS; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84872698573     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1135     Document Type: Article

References (33)

1. Jemal A, Siegal R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Robnett TJ, Machtay M, Stevenson JP, Algazy KM and HahnSM: Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma J Clin Oncol 19: 1344-1349, 2001.
3. Rusciano D and Burger MM: Why do cancer cells metastasize into particular organs? Bioessays 14: 185-194, 1992.
4. Nicolson GL: Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 204: 171-180, 1993.
5. Sierra A, Price JE, García-Ramirez M, Méndez O, López L and Fabra A: Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77: 357-368, 1997.
6. Yang I, Han SJ, Kaur G, Crane C and Parsa AT: The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 17: 6-10, 2010.
7. Langley RR, Fan D, Guo L, Zhang C, Lin Q, Brantley EC, McCarty JH and Fidler IJ: Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int J Oncol 35: 665-672, 2009.
8. Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK, Kim SH, KimIS, Hong JT, Sung JH, Son BC and Lee SW: E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. J Neurooncol 109: 219-227, 2012.
9. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
10. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, JauchKW and Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135, 2002.
11. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M and Ishikura H: Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98: 726-733, 2007.
12. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J, Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC and Fidler IJ: Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13: 286-298, 2011.
13. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, Iguchi H and Noda M: Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 28: 13-25, 2011.
14. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E and Apte RN: Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 186: 3462-3471, 2011.
15. Wu YZ, Hong JH, Huang HH, Dougherty GJ, McBride WH and Chiang CS: Mechanisms mediating the effects of IL-3 gene expression on tumor growth. J Leukoc Biol 68: 890-896, 2000.
16. Jiang XP, Yang DC, Elliott RL and Head JF: Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. Anticancer Res 31: 2899-2906, 2011.
17. Suarez Pestana E, Björklund G, Larsson R, Nygren P, Nilsson K and Bergh J: Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. Acta Oncol 35: 473-478, 1996.
18. Tse JC and Kalluri R: Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816-829, 2007.
19. Yu J, Ustach C and Kim HR: Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36: 49-59, 2003.
20. Raffaghello L, Cocco C, Corrias MV, Airoldi I and Pistoia V: Chemokines in neuroectodermal tumour progression and metastasis. Semin Cancer Biol 19: 97-102, 2009.
21. Zhang J, Patel L and Pienta KJ: CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21: 41-48, 2010.
22. Nakasone Y, Fujimoto M, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M, Sato S, Takehara K and Hasegawa M: Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am J Pathol 180: 365-374, 2012.
23. van Deventer HW, Serody JS, McKinnon KP, Clements C, Brickey WJ and Ting JP: Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. J Immunol 169: 1634-1639, 2002.
24. Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, Nunez N, Chen X, Mendoza A, Hong SH, Khanna C and Yakar S: Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 70: 57-67, 2010.
25. Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62: 1030-1035, 2002.
26. Sehgal SN, Baker H and Vézina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28: 727-732, 1975.
27. Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J and Wong ST: The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat 131: 425-436, 2012.
28. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M and Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63: 917-926, 2003.
29. Yang Z, Lei Z, Li B, Zhou Y, Zhang GM, Feng ZH, Zhang B, Shen GX and Huang B: Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci 101: 494-500, 2010
30. Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R, MolinoloAA and Gutkind JS: Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 71: 7103-7112, 2011.
31. Hussein O, Tiedemann K, Murshed M and Komarova SV: Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 314: 176-184, 2012.
32. Langley RR and Fidler IJ: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28: 297-321, 2007.
33. Gupta GP and Massagué J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.